MCC capacity expansion to 30,000 MTPA by Q3 FY27
12,000 MTPA MCC expansion at Dehli SEZ on track for commissioning in Q3 FY27, taking total cellulose-based excipient capacity to 30,000 MTPA.
SIGACHI / guidance tracker
Keep management guidance in view.
Sigachi Industries · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
expansion
CCS facility commissioning in Q3 FY27
1,800 TPA CCS disintegrant facility at Dehli SEZ progressing well and expected to be commissioned in Q3 FY27.
Double-digit EBITDA margin expected by FY28
Management expects EBITDA margins to recover to double-digit levels by FY28 as new capacities absorb overheads and operations normalize.
Cystic fibrosis API revenue of ₹250 Cr after 12 months
Company expects ₹250 crore revenue from cystic fibrosis API after commercialization, which is 12 months post-development.